Press release from PR Newswire
Keryx Biopharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
Monday, January 07, 2013
Keryx Biopharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference16:30 EST Monday, January 07, 2013Presentation Scheduled for Thursday, January 10th at 9:00 AM PSTNEW YORK, Jan. 7, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 31st Annual J.P. Morgan Healthcare Conference, being held January 7-10, 2013, in San Francisco, CA. Mr. Bentsur's presentation is scheduled to take place on Thursday, January 10th, at 9:00 AM Pacific Standard Time (12:00 PM EST). A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The U.S.-based Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Zerenex is also in Phase 2 development for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease. Keryx is headquartered in New York City. KERYX CONTACT:Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965E-mail: firstname.lastname@example.orgSOURCE Keryx Biopharmaceuticals, Inc.